skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: On Nov 28,BNS reported EPS of $1.65 vs $1.66 expected(e) plus offer to buy BBVA for $2.2b.For comparison purposes,CM(2.81 vs 2.59e),TD(1.36 vs 1.39e),RY(1.92 vs 1.87e) & NA(1.40 vs 1.38e).BMO reports on Dec 5.Reportedly,these banks are spending heavily on technology,& at the same time cutting costs.Heard through the grapevine that CM is revamping its system in order to increase both top & bottom line. Please comment on aforementioned offer by BNS.Is BNS still your top pick of the Canadian banks?Thanks for u usual great services & views.
Read Answer Asked by Peter on December 04, 2017
Q: Your recent report on SaaS players excluded ABT as a "top pick" yet it was a top pick by Peter on a recent BNN appearance. I have been in the red substantially ever since purchasing ABT on that recommendation. What do I do?

Carl
Read Answer Asked by Carl on December 04, 2017
Q: Per the G&M today, Absolute has "...withdrawn a resolution for its upcoming annual shareholder meeting...in order to secure the support of Institutional Shareholder Services to recommend that shareholders of the company vote 'for' all matters to be considered at the meeting." Do institutions hold a significant number Absolute's shares and does this note indicate the company is being "encouraged" to modify its stance in order to retain institutional support? I'm holding a small position at break-even and am wavering on continuing to do so. Your insight would be helpful.
Read Answer Asked by David on December 04, 2017
Q: I am losing faith in this company. The "growth"stock continues to slide yet 5i continues to recommend it. Where is the disconnect? What am I missing?
Read Answer Asked by Paul on December 01, 2017
Q: Hello 5i,
From time to time a well performing company misses on earnings estimates in a quarter but it does not necessarily mean that its longer term good performance and potential growth will slow.
What was the cause of the poor earnings per share result. Was the reasons for this miss merely a temporary hiccup or perhaps a longer term issue. What conclusion should one draw from this quarter's results? Are the views about this company change from your September report? Is the growth by acquisition theme and potential remain intact. What can we expect to see from the company in the next 6 and 12 months. Should I continue to hold or sell at this time.

Thanks for your excellent insights.
Joseph
Read Answer Asked by Joseph on November 30, 2017
Q: Disappointed in NFIs stock performance this last month - down about 14%. I regarded this as one of my ‘hang on and ignore’ stocks. I can’t find any negative stuff on it - seems all positive. Is it tax selling this early? I realize it is up on the year so I suppose this could be it. I think I am missing something tho. Pls enlighten me. Thks guys.
Read Answer Asked by Arthur on November 30, 2017
Q: Here we go again.The underwriters try to push the stock as high as possible,but in this case of ENB with limited success.After market closed today ENB announced it is going to the market again to raise financing to the tune of $1.5b of private placement of 33.5m of treasury shares @ $44.84(recent 52 week low of $43.91),At the same time it reconfirmed 10%pa increase in dividend for a number of years.Please advise who are the lead underwriter(s) & underwriters.I guess BMO is one as it did a glowing report in G&M @ end of last week.My purchase @ $50 is 10% higher than the. $44.84,so hopefully the gap can be bridged.Thanks for u usual great views & services.
Read Answer Asked by Peter on November 30, 2017
Q: A member just asked about CGX...maybe this is the reason...from TD:

Yesterday afternoon, it was confirmed that Cineworld Group plc (CINE-LN, not rated) is currently engaged in discussions about a possible all-cash acquisition of Regal Entertainment Group (RGC-US, not rated), the No. 2 U.S. exhibitor, at a price of US$23 per share, or ~US$3.6bln (~US$5.9bln including debt).
However, no agreement has been reached.
Impact: SLIGHTLY POSITIVE
A US$23 per share purchase price is a 26% premium to Monday's closing price, but a 44% premium from a week ago. This equates to ~9.0x and ~22.0x 2018 consensus EBITDA and EPS, respectively. Implications for CGX include:
■ The valuation being implied for Regal gives us confidence in the ~10.1x we are applying to CGX's theatre segment within our SOTP calculation. CGX is currently trading at 9.7x our 2018 EBITDA estimate, and our current $47.00 target price is based on an 11.0x EV/EBITDA multiple applied to our consolidated EBITDA estimate for the 12 months ending September 2019.
■ We do not believe that CGX is currently for sale; however, applying Regal's takeover valuation plus the historical 3.0x-4.0x multiple point premium to CGX's 2018 EBITDA suggests that CGX could be worth $50-$55 in a takeout.
However, given its market share, mix of high-margin businesses, and strong earnings profile, we believe that this range would be the floor price.
■ The selloff in CGX shares has been overdone, exacerbated by increasing investor short positions over the past few months. We believe that industry M&A — which could be a consequence of what is perceived to be the diminishing influence exhibitors wield over the major studios — should provide short-term support for the share price. Over the long term, we believe that valuation will start rising once it becomes more evident that Cineplex's ongoing diversification initiatives are lessening its dependence on Hollywood content and when there is greater clarity surrounding the impact of Premium Video on Demand (PVOD). We expect these to become clearer closer to 2019.
Post if you think appropriate.
Read Answer Asked by Silvia on November 29, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!